These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25155930)

  • 61. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
    Jansen A; Colbers EP; van der Ven AJ; Richter C; Rockstroh JK; Wasmuth JC; van Luin M; Burger DM
    HIV Med; 2013 Aug; 14(7):449-52. PubMed ID: 23506243
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.
    Busti AJ; Bedimo R; Margolis DM; Hardin DS
    J Investig Med; 2008 Feb; 56(2):539-44. PubMed ID: 18317438
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients.
    Gervasoni C; Riva A; Rizzardini G; Clementi E; Galli M; Cattaneo D
    Antivir Ther; 2015; 20(4):449-51. PubMed ID: 25279606
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
    Taburet AM; Piketty C; Chazallon C; Vincent I; Gérard L; Calvez V; Clavel F; Aboulker JP; Girard PM
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2091-6. PubMed ID: 15155205
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
    Yamada T; Mino Y; Naito T; Kawakami J
    J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir.
    Bruce RD; Altice FL
    AIDS; 2006 Mar; 20(5):783-4. PubMed ID: 16514314
    [No Abstract]   [Full Text] [Related]  

  • 67. Ritonavir-boosted atazanavir may be efficacious in HIV-infected patients concurrently receiving omeprazole.
    Chan-Tack KM; Edozien A
    Clin Infect Dis; 2006 May; 42(9):1344. PubMed ID: 16586398
    [No Abstract]   [Full Text] [Related]  

  • 68. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
    Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
    Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
    Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A probable drug-to-drug interaction between voriconazole and haloperidol in a CYP2C19 poor metabolizing patient. [corrected].
    Motta I; Calcagno A; Baietto L; D'Avolio A; De Rosa FG; Bonora S
    Infez Med; 2015 Dec; 23(4):367-9. PubMed ID: 26700090
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
    Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
    Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.
    Imamura CK; Furihata K; Okamoto S; Tanigawara Y
    J Clin Pharmacol; 2016 Apr; 56(4):408-13. PubMed ID: 26239045
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections.
    Resztak M; Zalewska P; Wachowiak J; Sobkowiak-Sobierajska A; Główka FK
    Eur J Clin Pharmacol; 2024 Nov; 80(11):1829-1840. PubMed ID: 39240338
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interaction of age and CYP2C19 genotypes on voriconazole steady-state trough concentration in Chinese patients.
    Du YX; Zhu YX; Li L; Yang J; Chen XP
    Pharmacogenet Genomics; 2024 Aug; 34(6):191-198. PubMed ID: 38747453
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.
    Haas DW; Koletar SL; Laughlin L; Kendall MA; Suckow C; Gerber JG; Zolopa AR; Bertz R; Child MJ; Hosey L; Alston-Smith B; Acosta EP;
    J Acquir Immune Defic Syndr; 2009 Mar; 50(3):290-3. PubMed ID: 19194314
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.
    Trubiano JA; Crowe A; Worth LJ; Thursky KA; Slavin MA
    J Antimicrob Chemother; 2015 Apr; 70(4):1161-5. PubMed ID: 25558073
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.
    Siccardi M; D'Avolio A; Baietto L; Gibbons S; Sciandra M; Colucci D; Bonora S; Khoo S; Back DJ; Di Perri G; Owen A
    Clin Infect Dis; 2008 Nov; 47(9):1222-5. PubMed ID: 18831695
    [TBL] [Abstract][Full Text] [Related]  

  • 78. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
    Owusu Obeng A; Egelund EF; Alsultan A; Peloquin CA; Johnson JA
    Pharmacotherapy; 2014 Jul; 34(7):703-18. PubMed ID: 24510446
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
    Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
    Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians.
    Chawla PK; Nanday SR; Dherai AJ; Soman R; Lokhande RV; Naik PR; Ashavaid TF
    Int J Clin Pharm; 2015 Oct; 37(5):925-30. PubMed ID: 26024717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.